Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
neurodegenerative disease
|
| gptkbp:affects |
central nervous system
substantia nigra |
| gptkbp:alsoKnownAs |
PD
|
| gptkbp:associatedWith |
gptkb:orthostatic_hypotension
gptkb:REM_sleep_behavior_disorder anxiety constipation hallucinations anosmia urinary problems impulse control disorders |
| gptkbp:causedBy |
loss of dopamine-producing neurons
|
| gptkbp:characterizedBy |
bradykinesia
postural instability rigidity tremor |
| gptkbp:complication |
gptkb:dementia
gptkb:pneumonia falls swallowing difficulties |
| gptkbp:diagnosedBy |
clinical evaluation
neurological examination response to levodopa |
| gptkbp:firstDescribed |
gptkb:James_Parkinson
1817 |
| gptkbp:hasNoCure |
true
|
| https://www.w3.org/2000/01/rdf-schema#label |
Parkinson's Disease
|
| gptkbp:ICD-10_code |
gptkb:G20
|
| gptkbp:managedBy |
symptomatic treatment
|
| gptkbp:MeSH_ID |
D010300
|
| gptkbp:namedAfter |
gptkb:James_Parkinson
|
| gptkbp:OMIM |
168600
|
| gptkbp:prevalence |
affects about 1% of people over 60
more common in people over 60 second most common neurodegenerative disease |
| gptkbp:progression |
progressive
chronic |
| gptkbp:riskFactor |
age
family history male gender exposure to toxins |
| gptkbp:studiedBy |
gptkb:alpha-synuclein
genetic factors Lewy bodies environmental factors |
| gptkbp:symptom |
gptkb:depression
muscle stiffness resting tremor shuffling gait sleep disturbances speech changes writing changes autonomic dysfunction slowed movement impaired balance |
| gptkbp:treatment |
gptkb:levodopa
occupational therapy physical therapy speech therapy MAO-B inhibitors deep brain stimulation dopamine agonists COMT inhibitors |
| gptkbp:bfsParent |
gptkb:Spasmodic_Movements
|
| gptkbp:bfsLayer |
6
|